Differences of the Immune Phenotype of Breast Cancer Cells after Ex Vivo Hyperthermia by Warm-Water or Microwave Radiation in a Closed-Loop System Alone or in Combination with Radiotherapy.
EGFR
breast cancer
danger signals
hyperthermia
immune checkpoint molecules
immunogenic cancer cell phenotype
immunotherapy
microwave-heating
multimodal tumor therapies
radiotherapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
27 Apr 2020
27 Apr 2020
Historique:
received:
16
03
2020
revised:
17
04
2020
accepted:
18
04
2020
entrez:
1
5
2020
pubmed:
1
5
2020
medline:
1
5
2020
Statut:
epublish
Résumé
The treatment of breast cancer by radiotherapy can be complemented by hyperthermia. Little is known about how the immune phenotype of tumor cells is changed thereby, also in terms of a dependence on the heating method. We developed a sterile closed-loop system, using either a warm-water bath or a microwave at 2.45 GHz to examine the impact of ex vivo hyperthermia on cell death, the release of HSP70, and the expression of immune checkpoint molecules (ICMs) on MCF-7 and MDA-MB-231 breast cancer cells by multicolor flow cytometry and ELISA. Heating was performed between 39 and 44 °C. Numerical process simulations identified temperature distributions. Additionally, irradiation with 2 × 5 Gy or 5 × 2 Gy was applied. We observed a release of HSP70 after hyperthermia at all examined temperatures and independently of the heating method, but microwave heating was more effective in cell killing, and microwave heating with and without radiotherapy increased subsequent HSP70 concentrations. Adding hyperthermia to radiotherapy, dynamically or individually, affected the expression of the ICM PD-L1, PD-L2, HVEM, ICOS-L, CD137-L, OX40-L, CD27-L, and EGFR on breast cancer cells. Well-characterized pre-clinical heating systems are mandatory to screen the immune phenotype of tumor cells in clinically relevant settings to define immune matrices for therapy adaption.
Identifiants
pubmed: 32349284
pii: cancers12051082
doi: 10.3390/cancers12051082
pmc: PMC7281749
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Bayerische Forschungsstiftung
ID : AZ 1261-17
Références
Cell Death Differ. 2001 Apr;8(4):327-34
pubmed: 11550084
Int J Mol Sci. 2019 Apr 12;20(8):
pubmed: 31013788
Strahlenther Onkol. 2017 May;193(5):351-366
pubmed: 28251250
Front Immunol. 2015 Oct 08;6:505
pubmed: 26500646
Front Immunol. 2017 Mar 08;8:231
pubmed: 28337197
Int J Hyperthermia. 2019;36(1):277-294
pubmed: 30676101
Cancers (Basel). 2020 Mar 03;12(3):
pubmed: 32138173
Sci Rep. 2019 Oct 7;9(1):14356
pubmed: 31591439
Int J Hyperthermia. 2012;28(6):528-42
pubmed: 22690925
Clin Cancer Res. 2017 Sep 1;23(17):5024-5033
pubmed: 28512174
Cancers (Basel). 2019 Nov 20;11(12):
pubmed: 31756933
Cancer Immunol Immunother. 2020 Feb;69(2):293-306
pubmed: 31953578
Strahlenther Onkol. 2009 Feb;185(2):120-6
pubmed: 19240999
Int J Radiat Oncol Biol Phys. 1986 Sep;12(9):1667-71
pubmed: 3759593
Breast Cancer Res Treat. 2004 Feb;83(3):249-89
pubmed: 14758095
Strahlenther Onkol. 2019 Apr;195(4):318-326
pubmed: 30607453
BMC Cancer. 2015 Oct 15;15:708
pubmed: 26472466
Cell. 2018 Dec 13;175(7):1731-1743.e13
pubmed: 30503213
PLoS One. 2020 Jan 6;15(1):e0227146
pubmed: 31905221
Mol Oncol. 2020 Feb 28;:
pubmed: 32112478
Int J Mol Sci. 2016 Aug 11;17(8):
pubmed: 27529227
Int J Hyperthermia. 2018 Nov;34(7):901-909
pubmed: 29749270
Cancer. 2020 Feb 15;126(4):850-860
pubmed: 31747077
Front Oncol. 2019 May 21;9:412
pubmed: 31165046
J Biol Chem. 1998 Jun 19;273(25):15540-5
pubmed: 9624143
Int J Hyperthermia. 2017 Jun;33(4):471-482
pubmed: 28049386
J Exp Clin Cancer Res. 2019 May 23;38(1):218
pubmed: 31122265
Adv Drug Deliv Rev. 2020 Mar 27;:
pubmed: 32229271
J Biol Chem. 1973 Sep 10;248(17):6251-3
pubmed: 4353636
Radiat Oncol. 2015 Sep 17;10:197
pubmed: 26383236
J Cancer Res Ther. 2018 Jan;14(1):150-154
pubmed: 29516978
Breast Care (Basel). 2015 Dec;10(6):408-12
pubmed: 26989361
Front Immunol. 2016 Dec 22;7:610
pubmed: 28066420
Immunity. 2020 Jan 14;52(1):17-35
pubmed: 31940268
J Thorac Dis. 2017 Oct;9(10):3840-3850
pubmed: 29268393
J Microw Power Electromagn Energy. 2007;41(1):44-64
pubmed: 18161416
J Control Release. 2016 Jan 28;222:47-55
pubmed: 26658073
Int J Hyperthermia. 2017 Jun;33(4):378-386
pubmed: 27951733
Int J Oncol. 2018 Aug;53(2):539-550
pubmed: 29901106
Front Oncol. 2017 Jun 30;7:132
pubmed: 28713771
JAMA Netw Open. 2019 May 3;2(5):e192535
pubmed: 31050774
Int J Hyperthermia. 2016;32(1):23-30
pubmed: 26754406
J Clin Oncol. 2018 Jun 1;36(16):1611-1618
pubmed: 29437535
Eur J Cancer. 2009 Jul;45(11):1969-78
pubmed: 19361982
Br J Cancer. 2015 Jan 6;112(1):95-102
pubmed: 25349974
Mol Oncol. 2018 Jan;12(1):3-20
pubmed: 29124875
BMC Cancer. 2018 May 11;18(1):556
pubmed: 29751789
Lancet Oncol. 2013 Oct;14(11):1086-1094
pubmed: 24055415
Radiother Oncol. 2011 Oct;101(1):109-15
pubmed: 21704416
Strahlenther Onkol. 2018 Jun;194(6):509-519
pubmed: 29500551
Oncotarget. 2017 Aug 5;8(53):90825-90841
pubmed: 29207606
In Vitro. 1974 Jan-Feb;9(4):239-45
pubmed: 4471183
Strahlenther Onkol. 2016 Apr;192(4):199-208
pubmed: 26931319
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Int J Hyperthermia. 2016;32(1):50-62
pubmed: 26758036
Autoimmunity. 2009 May;42(4):311-3
pubmed: 19811286
Ann N Y Acad Sci. 2013 May;1284:1-5
pubmed: 23651186
Semin Oncol. 2014 Dec;41(6):714-29
pubmed: 25499632
Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1216-1224
pubmed: 29165286
Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):381-91
pubmed: 10974451
Oncotarget. 2016 Dec 20;7(51):84082-84092
pubmed: 27556507
Oncogene. 2020 Jan;39(1):187-203
pubmed: 31467431
Cancers (Basel). 2020 Mar 06;12(3):
pubmed: 32155740
Cancer Treat Rev. 2015 Nov;41(9):742-53
pubmed: 26051911
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
Biomed Res Int. 2018 Mar 15;2018:8321871
pubmed: 29736399
Front Oncol. 2016 Jun 20;6:141
pubmed: 27379203
JAMA Oncol. 2018 Apr 1;4(4):483-492
pubmed: 29450452
Oncoimmunology. 2016 Sep 20;5(11):e1235107
pubmed: 27999753
Front Oncol. 2019 Aug 28;9:805
pubmed: 31555582
Breast Care (Basel). 2015 Apr;10(2):109-16
pubmed: 26195939
Bioelectromagnetics. 2008 May;29(4):324-30
pubmed: 18240290
Front Oncol. 2019 Mar 08;9:134
pubmed: 30906734
Mol Cancer. 2019 Jan 15;18(1):10
pubmed: 30646912
Methods. 2013 Jun 1;61(2):90-7
pubmed: 23403105
Front Oncol. 2018 Dec 13;8:612
pubmed: 30619752
Cancers (Basel). 2019 Jan 09;11(1):
pubmed: 30634444